BMJ：他汀类药物未能降低感染风险
2011-12-09 MedSci原创 MedSci原创
荷兰一项研究显示，来自大样本（≥100例）随机对照试验的证据不支持他汀类药物可降低感染风险的假设。论文于11月29日在线发表于《英国医学杂志》（BMJ）。 研究者检索了Medline、Embase和Cochrane图书馆，纳入他汀类药物相关的随机安慰剂对照试验11项（30947例受试者，随访时间≥1年）。 结果为，共4655例受试者（他汀类药物组2368例，安慰剂组2287例）在治
荷兰一项研究显示，来自大样本（≥100例）随机对照试验的证据不支持他汀类药物可降低感染风险的假设。论文于11月29日在线发表于《英国医学杂志》（BMJ）。
研究者检索了Medline、Embase和Cochrane图书馆，纳入他汀类药物相关的随机安慰剂对照试验11项（30947例受试者，随访时间≥1年）。
结果为，共4655例受试者（他汀类药物组2368例，安慰剂组2287例）在治疗期间出现感染。荟萃分析显示，他汀类药物对感染风险[相对危险度（RR）为1.00]或感染相关性死亡（RR=0.97）无影响。
原始文献：
评价：
According to the results of a systematic review and meta-analysis published early online in the British Medical Journal (BMJ), findings from placebo-controlled statin trials do not support the hypothesis that statins reduce the risk of infections.
The authors note that statins are known to have anti-inflammatory and immunomodulatory properties, in addition to their cholesterol-lowering effects; these may be beneficial in the management of infection. Although population-based studies over the past few years have reported associations between statin use and a reduced risk of infectious outcomes, there are potential biases and confounders at play and the association is therefore inconclusive.
The purpose of the current study was to determine whether the beneficial association between statins and infections seen in observational studies is causal. The authors hypothesised that if such an effect exists, it would be possible to detect it in the results of large randomised, placebo-controlled studies. They therefore carried out a systematic review of the literature (Medline in PubMed, Embase, and the Cochrane central register of controlled trials; to March 2011) to identify such studies, and included those enrolling a minimum of 100 participants, with follow-up for at least one year, that reported infection or infection related death and were published in English. After screening, a total of 11 studies (n=30,947; 45.6% received statin therapy and 54.4% received placebo) were included in the analysis, with an average follow-up of 3.3 (range 1-5.1) years.
The authors report that 4,655 of the study participants (2,368 randomised to statins and 2,287 to placebo) reported an infection during treatment. Meta-analysis showed no effect of statins on the risk of infections (relative risk 1.00, 95% CI 0.96 to 1.05; p=0.93) or on infection related mortality (0.97, 0.83 to 1.13; p=0.71). The included studies showed low heterogeneity and the exclusion of data from one study that lacked double-blinding did not significantly alter the results.
The authors compare their results with those from other studies and note some of the limitations of their analysis, for example the inclusion of only 11 studies precluded the conduct of subgroup analyses for statin dose, type, patient characteristics and type of infection. There was also no information on the validity of the infectious outcomes, although the authors say that they would expect these events to be noticed and reported.
The authors conclude that their analysis provides no evidence to support the hypothesis that statin use decreases the risk of infections. They say this weakens any argument for conducting a randomised controlled trial of statins for infection prevention, and suggest that a better approach would be to push reporting of infectious outcomes in detail whenever statin trials are undertaken - this could identify potential subgroups in whom such testing may be more worthwhile.
延伸阅读：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
#他汀类药#
30
#BMJ#
26
This is a really intelligent way to asnewr the question.
116